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Traditional Chinese medicine (TCM) is widely prescribed in
China and some Asian countries. The medicines are complex
systems in which the various constituents exert a synergistic or
antagonistic effect1. Studies of the pharmacokinetics (PK) of
these multi-component systems usually focus on the active
constituents in single-item formulations or simple prescrip-
tions2. However, few studies have investigated the PK of
complex prescriptions containing multiple herbs. The aim of
the current work was to study the PK of the active constitu-
ents in the multi-herbal prescription known as Xiao-Xu-Ming
Decoction (XXMD).
The use of XXMD was ﬁrst recorded in the medical text
Bei Ji Qian Jin Yao Fang, written in the Tang Dynasty by the
ancient Chinese therapist, Simiao Sun. The formula includes
the following 12 herbs: Saposhnikovia divaricata (Turcz.)
Schischk., Scutellaria baicalensis Georgi, Paeonia lactiﬂora
Pall., Glycyrrhiza uralensis Fisch., Zingiber ofﬁcinale Rosc.,
Stephania tetrandra S. Moore, Panax ginseng C. A. Mey.,
Cinnamomum cassia Presl, Prunus armeniaca L. var. ansu
Maxim., Ephedra sinica Staph, Ligusticum chuanxiong Hort.
and Aconitum carmichaeli Debx. in the ratio 3:3:3:3:3:3:6:6:
6:9:9:9 on a dry weight basis. The active fraction was screened
by Wang et al.3, and shown to exert a similar pharmacological
effect to that of XXMD in treating theoplegia and its sequelae.
In a previous study4, we reported the active compounds
and their metabolites after oral administration of the active
fraction of XXMD to rats. Oroxylin A-7-O-glucuronide,
wogonoside, liquiritigenin, cimifugin, 5-O-methylvisammiol,
glycyrrhizic acid and glycyrrhetinic acid were all the active
components of the active fraction. Oroxylin A showed the
neuroprotective or memory enhancing effects through activa-
tion of synaptic NMDA receptor and improved Ab25–35
peptide-induced memory impairment through the GABAergic
neurotransmitter system5,6. Oroxylin A-7-O-glucuronide was
the major metabolite of Oroxylin A7. Wogonoside has been
reported to display anti-allergic and anti-oxidative activities8,9.
Liquiritigenin showed neuroprotective effect against Ab25-35-
induced neurotoxicity and decreased the secretion of Ab1-
4010. Cimifugin and 5-O-methylvisammiol, two chromones
derived from Saposhnikovia divaricata (Turcz.) Schischk.,
show similar activites such as signiﬁcant analgesic, antipyretic,
anti-inﬂammatory and anti-platelet aggregation11. Glycyr-
rhizic acid and glycyrrhetinic acid exhibited the activities of
anti-allergy, anti-oxidation, anti-inﬂammatory, anti-viral and
anti-cancer12–16. Since the activity of the above compounds
related to the activity of XXMD, they might be the material
basis of XXMD effects. The pharmacokinetic study of the
above components would help to elucidate the mechanism of
XXMD and provide reference for other research of traditional
Chinese medicine.
So far, no analytical method has been reported for systematic
pharmacokinetics study of the seven compounds from XXMD
by HPLC–MS and HPLC–MS/MS. In this paper, we developed
and validated three methods for quantiﬁcation and pharmaco-
kinetic studies of oroxylin A-7-O-glucuronide, wogonoside,
liquiritigenin, cimifugin, 5-O-methylvisammiol, glycyrrhizic acid
and glycyrrhetinic acid in plasma after oral administration of
XXMD to rats in order to provide scientiﬁc evidence for
elucidating the material basis and pharmaceutical mechanism
of XXMD and improve the understanding of TCM.2. Materials and methods
2.1. Chemicals and reagents
The active fraction of XXMD and oroxylin A-7-O-glucur-
onide (purity499%) were kind gifts from Prof. Hailin Qin
(Institute of Materia Media, Chinese Academy of Medical
Science & Peking Union Medical College, Beijing, China).
Cimifugin, glycyrrhetinic acid and three internal standards (IS,
phenacetin, carbamazepine and icariin) were purchased from
National Institute for the Control of Pharmaceutical and
Biological Products (purities499%, Beijing, China). Wogono-
side (purity499%) was ordered from the Shanghai Usea Biotech
Co., Ltd. (Shanghai, China). Liquiritigenin (purity499%) was
obtained from the Dalian Fusheng Pharmaceutical Co., Ltd.
(Dalian, China). Glycyrrhizic acid (purity498%) was purchased
from Shanghai Winherb Medical S&T Development Co., Ltd
(Shanghai, China). 5-O-methylvisammiol was isolated and
puriﬁed in our laboratory with the purity more than 98% by
HPLC-DAD. The chemical structures of 7 compounds from
XXMD and IS are shown in Fig. 1.
Acetonitrile of LC/MS reagent grade was obtained from
Mallinckrodt Baker, Inc. (Phillipsburg, NJ, USA). Deionized
water was puriﬁed using a Millipore water puriﬁcation
system (Millipore, Billerica, MA, USA). Analytical grade
acetic acid and formic acid were obtained from Merck Inc.
(Darmstadt, Germany). Analytical grade methanol and ethyl
acetate were purchased from Beijing Chemical Corp. (Beijing,
China).
The active fraction of XXMD for oral administration
was dissolved in redistilled water with a ﬁnal concentration
of 250 mg/mL, and 0.5% Tween 80 was added as solution
adjuvant. The concentrations of liquiritigenin, oroxylin A-7-
O-glucuronide, wogonoside, cimifugin, 5-O-methylvisammio-
side, glycyrrhizic acid and glycyrrhetinic acid in dosed solution
were 0.84, 1.00, 1.50, 1.06, 3.12, 1.60 and 1.13 mg/mL,
respectively, determined by HPLC.2.2. Instrument and analytical conditions
For the determination of cimifugin and 5-O-methylvisammiol,
the assay was performed on a Thermo Finnigan LTQ system
(Thermo Fisher, Co., Ltd., San Jose, CA, USA) consisting of
an LC connected to a linear ion trap MS analyzer with an
electrospray ionization (ESI) interface available in either
positive-ionization or negative-ionization mode. An Xcalibur
1.4 workstation (Thermo Fisher, Co., Ltd., San Jose, CA,
USA) was used for LC–MS control and data acquisition. The
HPLC separations were achieved using an Inertsil ODS-3
column (100 mm 2.1 mm, 3 mm). The mobile phase consisted
of acetonitrile and 0.1% aqueous formic acid (30:70, v/v) with
a ﬂow rate of 0.2 mL/min for 6 min. The injection volume was
set at 10 mL. The temperature of column oven was maintained
at 30 1C. The optimum operating parameters of the ESI
interface in positive mode were as follows: sheath gas ﬂow
rate at 35 arb, aux gas ﬂow rate at 10 arb, sweep gas ﬂow rate
at 5 arb, spray voltage at 4.0 kV, capillary temperature at
275 1C, capillary voltage at 4.0 kV and tube lens at 90 V.
Quantiﬁcation was achieved using full scan mode of ion for
5-O-methylvisammiol at m/z 290.5–291.5, for cimifugin at m/z
306.5–307.5 and for phenacetin (IS) at m/z 179.5–180.5.
Table 1 Optimized mass parameters for liquiritigenin, oroxylinA-7-O-glucuronide, wogonoside, glycyrrhizic acid glycyrrhetinic
acid and their internal standards (IS).
Analyte Precursor
ion (m/z)
MS1 Res Product
ion (m/z)
MS2 Res Dwell (ms) Fragmentor
(V)
CE (V) Polarity
Liquiritigenin 255 wide 119 Uint 50 120 25 Negative
Oroxylin A-7-O-glucuronide 459 wide 268 Uint 50 120 30 Negative
Wogonoside 459 wide 268 Uint 50 120 30 Negative
IcariinðISÞ 675 wide 513 Unit 50 180 3 Negative
Glycyrrhizic acid 823.1 Unit 453.3 Unit 200 150 30 Positive
Glycyrrhetinic acid 471 Unit 291.3 Unit 200 135 30 Positive
Carbamazepine (IS) 237.1 Unit 179 Unit 200 135 35 Positive
Figure 1 The chemical structures of the seven analytes and three internal standards (IS). 1, liquiritigenin; 2, oroxylin A-7-O-glucuronide;
3, wogonoside; 4, cimifugin; 5, 5-O-methylvisammiol; 6, glycyrrhizic acid; 7, glycyrrhetinic acid.
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wogonoside, liquiritigenin, glycyrrhizic acid and glycyrrhetinic
acid, the research were performed on an Agilent 6410B triple
quadrupole LC–MS system (Agilent Corporation, MA, USA)
consisting of an Agilent 1200 RRLC system (Agilent Corpora-
tion, MA, USA) connected to a triple quadrupole MS
analyzer with an electrospray ionization (ESI) interface usable
in either positive-ionization or negative-ionization mode. A
MassHunter workstation was used for LC–MS/MS control
and data acquisition (Agilent Corporation, MA, USA).
The separation of oroxylin A-7-O-glucuronide, wogonoside
and liquiritigenin was carried out on a Waters Symmetry C18
column (100 mm 2.1 mm, 3.5 mm). The mobile phase con-
sisted of acetonitrile and 0.2% aqueous acetic acid (30: 70, v/v)
with a ﬂow rate of 0.3 mL/min for 10 min; the column oven
was maintained at 30 1C. The injection volume was set at 5 mL.
The optimum operating parameters of the ESI interface were
as follows: Source, ESI; Polarity, Negative; Nebulizer, 35 psi;
Dry gas, 9 L/min; Dry Temp, 350 1C; Capillary voltage,4000 V; Delta EMV, 300 V; The LC eluent ﬂow over a period
of 0.0–1.0 min was not introduced to the mass spectrometer
for data acquisition. Quantiﬁcation was achieved using multi-
ple-reaction-monitoring (MRM) mode. The operating para-
meters of MRM were listed in Table 1.
The separation of glycyrrhizic acid and glycyrrhetinic
acid was achieved on an Agilent ZORBAX SB-C18 column
(100 mm 2.1 mm, 3.5 mm) with acetonitrile (A)–0.4% aqu-
eous formic acid (B) as mobile phase at a ﬂow rate of 0.2
mL/min, using a liner gradient of 15% B over 0–0.5 min, 15–
30% B over 0.5–1 min, 30% B over 1–1.5 min, 30–90% B over
1.5–5 min, 90% B over 5–7.4 min, and the composition
returned to the initial condition within 0.1 min and then was
maintained for 7.5 min. The injection volume was set at 10 mL.
The optimum operating parameters of the ESI interface were
as follows: Source, ESI; Polarity, Positive; Nebulizer, 40 psi;
Dry gas, 9 L/min; Dry Temp, 350 1C; Capillary voltage,
4000 V; Delta EMV, 300 V. The LC eluent ﬂow over a period
of 0.0–3.0 min was not introduced to the mass spectrometer
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ple-reaction-monitoring (MRM) mode. The operating para-
meters of MRM were listed in Table 1.
2.3. Sample preparation
To analyze liquiritigenin, oroxylin A-7-O-glucuronide and
wogonoside, a 500 mL aliquot of plasma was transferred into
an Eppendorf tube, and then 50 mL of icariin (IS) working
solution was added and vortex-mixed thoroughly. The plasma
sample was loaded onto an SPE cartridge, which had been
preconditioned with 1 mL methanol followed by 1 mL water.
The cartridge was washed with 1 mL methanol–water (5:95, v/v)
followed by elution with 3 mL methanol under reduced
pressure(30 kPa). The methanol eluant was collected, and
evaporated to dryness at 35 1C under a gentle nitrogen stream.
Then, the residue was reconstituted in 100 mL methanol–water
(50:50, v/v). After centrifugation at 15,493 g for 10 min at
23 1C, 5 mL of the supernatant aliquot was injected into the
HPLC–MS/MS system.
To analyze cimifugin and 5-O-methylvisammiol, plasma
sample (50 mL) was spiked with 950 mL of physiological saline
and 50 mL of phenacetin (IS) solution, vortex-mixed for 30 s,
followed by addition of 3 mL acetic ether, then vortex-mixed for
60 s and centrifugated at 1,721 g for 10 min at room tempera-
ture. 2.5 mL organic phase was transferred to a clean ﬂask and
evaporated to dryness at 35 1C under vacuum. The residue was
reconstituted in 100 mL of acetonitrile–water (40:60, v/v) and
10 mL of the aliquot was injected into the LC–MS system.
To analyze glycyrrhizic acid and glycyrrhetinic acid, 20 mL
of the carbamazepine (IS) solution and 3 mL of methanol were
added to 500 mL of plasma sample, then mixed by vortex for
30 s and centrifuged at 1,721 g for 10 min at room tempera-
ture (23 1C). The supernatant was dried under a stream of N2.
The residue was reconstituted in 100 mL of methanol, and then
centrifuged at 15,493 g for 10 min at room temperature
(23 1C). 10 mL of the supernatant aliquot was injected into the
HPLC–MS/MS system.
2.4. Stock solution, calibration curve and quality control
(QC) samples
Liquiritigenin, oroxylin A-7-O-glucuronide, wogonoside, cimi-
fugin, 5-O-methylvisammiol, glycyrrhizic acid and glycyrrhe-
tinic acid were all prepared in methanol at ﬁnal concentrations
of 102.0, 75.0, 100.0, 104.0, 115.0, 5.02 and 12.38 mg/mL,
respectively. A series of working solutions of these analytes
were obtained by further diluting the stock solutions with
methanol. The internal standard solution of icariin, phenace-
tin and carbamazepine was prepared at ﬁnal concentrations of
500, 80 and 100 ng/mL in methanol. All solutions were stored
at 4 1C prior to analysis.
For the determination of liquiritigenin, oroxylin A-7-O-
glucuronide and wogonoside, the standard calibration curves
and QC samples were prepared by spiking the 500 mL of blank
rat plasma with 50 mL of standard working solutions and
50 mL icariin (IS) standard solution. The plasma concentration
ranges of liquiritigenin, oroxylin A-7-O-glucuronide and
wogonoside were 2.55–2.04 103, 1.88–1.50 103 and 2.50–
2.00 103 ng/mL, respectively. The QC samples were prepared
at concentrations of 5.10, 30.6, 306 and.53 103 ng/mL forliquiritigenin, 3.75, 22.5, 225 and 1.12 103 ng/mL for orox-
ylin A-7-O-glucuronide and 5.00, 30.0, 300 and 1.50 103
ng/mL for wogonoside.
For the determination of cimifugin and 5-O-methylvisam-
miol, to prepare biological calibration curves and QC samples,
50 mL blank rat plasma was added with 950 mL of physiolo-
gical saline, 10 mL of respective working solution of 5-O-
methylvisammiol and cimifugin, and 50 mL of the phenacetin
(IS) solution. The ﬁnal concentrations of biological calibration
standards of 5-O-methylvisammiol and cimifugin were within
the ranges of 11.5–230.0 ng/mL and 10.4–936.0 ng/mL, respec-
tively. QC samples were prepared at concentrations of 11.5,
46.0, 115.0 and 230.0 ng/mL for 5-O-methylvisammiol and
10.4, 83.2, 312.0 and 624.0 ng/mL for cimifugin.
For the determination of glycyrrhizic acid and glycyrrhetinic
acid, the samples for standard calibration curves and QC were
prepared by spiking the blank 500 mL rat plasma with 20 mL of
standard working solutions and 20 mL of carbamazepine (IS)
standard solution. The ﬁnal biological calibration standards of
glycyrrhizic acid and glycyrrhetinic acid were within the range
of 5.02–803 ng/mL and 12.4–2229 ng/mL, respectively. The QC
samples were prepared at concentrations of 20.1, 80.3 and
402 ng/mL for glycyrrhizic acid and at concentrations of 49.5,
198 and 991 ng/mL for glycyrrhetinic acid in the same manner.
2.5. Method validation
2.5.1. Speciﬁcity
Blank rat plasma, blank plasma spiked with 7 analytes and the
IS, and plasma sample after administration were analyzed by
the established LC–MS or LC–MS/MS methods to observe the
interference from endogenous substances with the analytes.
2.5.2. Linearity and lower limits of quantiﬁcation (LLOQ)
Linearity of the method was evaluated by calibration stan-
dards and determined by plotting the peak area ratio of
analytes to IS in the rat plasma. A least-squares linear
regression method (1/x2 weighting) was used to determine
the slope, intercept and correlation coefﬁcient (r) of linear
regression equation. The lower limit of quantiﬁcation (LLOQ)
was determined by spiked blank plasma samples.
2.5.3. Precision and accuracy
The precision and accuracy of the methods were assessed by
analysis of QC samples at three or four concentration levels,
along with an independent calibration curve for quantitation.
The precision was evaluated by the intra- and inter-day
variability with relative standard deviation (RSD). For intra-
day precision, the samples were consecutively analyzed six
times in a single day; for inter-day precision, this procedure
was repeated on six consecutive days. The accuracy was
expressed as the percentage of measured concentration in
spiked concentration. The criteria for acceptability of the data
included accuracy within 85–115%, and precision with RSD
less than 15%, except for LLOQ, with accuracy within
80–120%, and RSD less than 20%.
2.5.4. Extraction recovery
The extraction recoveries of 7 analytes were determined by
comparing the measured concentration from blank plasma
spiked with analytes with nominal concentration.
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The stability of analytes was investigated by analysis of QC
samples with three or four concentration levels, including (a)
intra-day stability: stability of the extracted samples at room
temperature for 24 h, (b) inter-day stability: stability of the
extracted samples at room temperature for 6 days, (c) freeze–
thaw stability: stability of after three freeze–thaw cycles with
the frozen temperature of 80 1C and thawing temperature of
23 1C and (d) long term stability: stability of plasma samples
at 80 1C for 10 days. All the assays were performed in three
replicates.2.6. Application of the method and pharmacokinetic study
Male Wistar rats (190720 g) were obtained from the Institute
of Laboratory Animals Sciences, Chinese Academy of Medical
Sciences and Peking Union Medical College (Beijing, China).
They were kept in an environmentally controlled breeding
room for 3 days before starting the experiments and fed with
standard laboratory food and water. Prior to the experiments
rats were fasted in a metabolic cage and maintained with
physiological saline for 24 h. 75 Rats were randomized
according to the body weight, grouped ﬁve per three time
points, so that the blood sample at three different time points
would be collected from the same group. Then the rats were
given the active fraction of XXMD at a dose of 2.0 g/kg (the
weight of the active fraction of XXMD/ body weight) by oral
administration. Rat blood samples were collected after admin-
istration at 2, 5, 10, 15, 20, 30, 40, 45 min, 1, 1.25, 1.5, 1.75,
2.1, 1.5, 2, 3, 4, 5, 6, 7, 7.5, 8, 8.5, 9, 10, 11, 12, 13, 14, 15,
16, 17, 18, 19, 20, 22, 24, 26, 30 and 32 h. Blood samples
were immediately heparinized and centrifuged at 1,721 g for
10 min at room temperature (23 1C). The supernatants were
placed into 1.5 mL polypropylene tubes and stored at 80 1CFigure 2 Representative chromatograms of (A) blank plasma, (B) bla
plasma sample taken 2 min after oral administration of the active fra
3, wogonoside.until the assay was performed. All protocols and procedures
were approved by The Animal Care & Welfare Committee,
Institute of Materia Medica, CAMS & PUMC.3. Results and discussion
3.1. Method validation
3.1.1. Speciﬁcity
The 7 constituents exhibited different physical and chemical
properties, so three analytical methods were established and
validated for rapid and accurate determination of the 7
analytes in rat plasma. Typical chromatograms of blank rat
plasma, blank plasma spiked with the 7 analytes and IS, and
plasma sample after administration are shown in Figs. 2–4.
Under the assay conditions, there was no signiﬁcant chroma-
tographic interference around the retention times of the 7
analytes and IS in blank plasma.
3.1.2. Linearity and LLOQs
The standard curves of the 7 analytes all exhibited good linearity
with the coefﬁcients of correlation (r) better than 0.996. The
LLOQs are appropriate for quantitative detection of the 7 analytes
in the pharmacokinetic studies. Linear ranges, regression equa-
tions, LLOQs, and correlation coefﬁcients obtained from typical
calibration curves are shown in Table 2.
3.1.3. Precision and accuracy
The measured concentrations of QC samples of the 7 analytes
were calculated from the biological calibration curves. The
results are shown in Table 3. The RSD of the overall intra-
and inter-day precisions were less than 11%, and the accuracy
ranged 88.7–113%.nk plasma spiked with mixed standard and icariin (IS), and (C) a
ction of XXMD. 1, liquiritigenin; 2, oroxylin A-7-O-glucuronide;
Figure 3 Representative chromatograms of (A) blank plasma, (B) blank plasma spiked with a mixed standard (cimifugin, 5-O-
methylvisamminol) and phenacetin (IS), and (C) a plasma sample taken 5 min after oral administration of the active fraction of XXMD.
4, cimifugin; 5, 5-O-methylvisammiol.
Figure 4 Representative chromatograms of (A) blank plasma, (B) blank plasma spiked with a mixed standard and carbamazepine (IS),
and (C) a plasma sample taken 11 h after oral administration of the active fraction of XXMD. 6, glycyrrhizic acid; 7, glycyrrhetinic acid.
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The extraction recoveries determined for the 7 analytes are
shown in Table 4. At three or four concentration levels of the
7 analytes, the extraction recoveries were all in the range of
89.7–113%. These results demonstrated that the values were
all in the acceptable ranges.3.1.5. Stability
The stability was evaluated by analysis of QC samples at
three or four levels for intra-day stability, inter-day
stability, freeze–thaw stability and long term stability.
The RSD of the stability precisions were less than 15%,
and the accuracy ranged from 85% to 115%.The results
Table 2 Results of linear regression of calibration curves of the seven analytes in rat plasma.
Analyte Linear range (ng/mL) Regression equation r LLOQ (ng/mL)
Liquiritigenin 2.55–2040 Y¼0.0116Xþ0.101 0.999 2.55
Oroxylin A-7-O-glucuronide 1.88–1500 Y¼0.0053Xþ0.059 0.998 1.88
Wogonoside 2.50–2000 Y¼0.0061Xþ0.049 0.999 2.50
Cimifugin 10.4–936 Y¼0.0299Xþ0.219 0.998 5.20
5-O-Methylvisammiol 11.5–230 Y¼0.0572X0.0843 0.997 5.75
Glycyrrhizic acid 5.02–803 Y¼0.0052Xþ0.0036 0.996 5.02
Glycyrrhetinic acid 12.4–2229 Y¼0.0002X0.0003 0.999 12.4
Table 3 Precision and accuracy of the seven analytes in rat plasma.
Analyte Plasma
conc.
(ng/mL)
Intra-day (n¼6) Inter-day (n¼6)
Founda
(ng/mL)
RSD
(%)
Accuracyb
(%)
Founda
(ng/mL)
RSD
(%)
Accuracyb
(%)
Liquiritigenin 5.10 5.3070.12 2.4 104 5.0270.21 4.2 98.5
30.6 30.070.81 2.7 98.0 30.071.02 3.4 97.9
306 31473.14 1.0 103 31678.32 2.6 103
1530 1.64 103736.1 2.2 107 1.57 103743.6 2.8 102
Oroxylin A-7-O-
glucuronide
3.75 4.1870.12 2.9 111 3.9770.26 6.5 106
22.5 23.470.95 4.0 104 23.570.78 3.3 104
225 22676.17 2.7 101 220713.6 6.2 97.8
1120 1.24 103736.6 3.0 110 1.17 103762.4 5.3 104
Wogonoside 5.00 5.1670.49 9.4 103 5.1270.18 3.4 103
30.0 26.870.42 1.6 89.2 28.571.43 5.0 95.1
300 29075.67 2.0 96.7 29879.41 3.2 99.4
1500 1.60 103752.6 3.3 107 1.53 103754.9 3.6 102
5-O-Methylvisa-mminol 11.5 12.1870.43 3.6 106 11.9771.08 9.0 104
46.0 41.1571.37 3.3 89.5 43.6974.46 10 95.0
115.0 106.3675.06 4.7 92.5 102.4179.96 9.7 89.1
230.0 239.0379.13 3.8 104 224.15710.90 4.9 97.5
Cimifugin 10.4 10.3170.57 5.5 99.1 11.3371.06 9.4 109
83.2 87.3471.30 1.5 105 85.9778.65 10 103
312.0 319.2179.98 3.1 102 308.13732.91 11 98.8
624.0 602.06713.47 2.2 96.5 609.55715.88 2.6 97.7
Glycyrrhizic acid 20.1 21.470.5 2.4 106 19.170.8 4.4 95.3
80.3 82.677.5 9.0 103 79.275.7 7.1 98.5
402 41779.3 2.2 104 438725.8 5.9 109
Glycyrrhetinic acid 49.5 52.173.5 6.7 105 52.274.1 7.8 105
198 18675.2 2.8 93.9 183713.0 7.1 92.4
991 1150712.8 1.1 116 909740.1 4.4 91.8
aThe values are means7SD of six experiments.
bAccuracy (%)¼mean of measured concentration/nominal concentration 100%.
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were stable.3.2. Pharmacokinetic study
The established method was successfully applied to analyze all
the 7 analytes in rat plasma samples after oral administration
of the active fraction of XXMD. The mean concentration
(n¼5) versus time proﬁle was shown in Fig. 5. The non-compartmental pharmacokinetic parameters were obtained
according to the mean plasma concentrations of the 7 analytes
by Drug and Statistics for Windows (DAS) Ver2.0 program
(Table 5).
The compounds existed in the active fraction of XXMD are
very complex, and the pharmacokinetics of the 7 analytes are
also remarkably non-typical. The double-peak or multi-peak
phenomenon was observed from the concentration–time curves
of the 7 analytes. And there was an obvious selectivity for the
absorption of the 7 compounds. 5-O-methylvisammioside is the
Table 4 Extraction recovery of the seven compounds in plasma (n¼6).
Analyte Plasma conc. (ng/mL) Mean7SD (RSD) Recoverya (%) RSD (%)
Liquiritigenin 5.10 5.7870.26 113 4.5
30.6 30.172.19 98.4 7.3
306 29276.04 95.5 2.1
1.53 103 1.44 103730.6 94.2 2.1
Oroxylin A-7-O-glucuronide 3.75 4.0070.41 107 10
22.5 23.170.30 103 1.3
225 218712.6 96.8 5.8
1.12 103 1.13 103758.4 100 5.2
Wogonoside 5.00 4.9170.32 98.2 6.4
30.0 27.871.07 92.6 3.9
300 281713.4 93.8 4.8
1.50 103 1.44 103781.3 95.8 5.7
5-O-methylvisamminol 11.5 11.9770.28 104 2.4
46.0 41.2571.00 89.7 2.4
115.0 104.8177.07 91.1 6.7
230.0 240.2278.20 104 3.4
Cimifugin 10.4 10.1570.70 97.6 6.9
83.2 87.7772.26 106 2.6
312.0 320.95712.79 103 4.0
624.0 606.20713.79 97.1 2.3
Glycyrrhizic acid 20.1 19.871.6 98.8 8.2
80.3 90.476.9 113 7.6
402 399728.9 99.4 7.3
Glycyrrhetinic acid 49.5 51.276.3 103 12
198 17775.4 89.2 3.0
991 878724.2 88.7 2.8
aRecovery (%)¼mean of measured concentration/nominal concentration 100%.
Figure 5 Mean plasma concentration–time proﬁle of the seven active components in rat plasma after oral administration of the active
fraction of XXMD.
HPLC–MS and HPLC–MS/MS analysis of seven active constituents of Xiao-Xu-Ming decoction 195richest component in the active fraction of XXMD; however, it
could not be detected, and 5-O-methylvisammiol was detected
in dosed rat plasma. It means that 5-O-methylvisammiol was
the metabolite of 5-O-methylvisammioside, so the Tmax of 5-O-
methylvisammiol was very long, at 8 h. Wogonoside and
glycyrrhizic acid were the secondary richest components in
active fraction, and wogonoside showed the highest Cmax and
AUC0t The concentration–time curves of wogonoside showeddouble-peak phenomenon (Tmax of ﬁrst peak at 0.15 min and
the second peak at 16 h), and was similar with that of
wogonoside after oral administration of Huangqin decoction
to rats17.
Both glycyrrhizic acid and glycyrrhetinic acid were con-
tained in the active fraction; the content of glycyrrhizic acid
(1.6 mg/mL) in XXMD was a little higher than glycyrrhetinic
acid (1.13 mg/mL). The proﬁles of concentration–time of
Table 5 Mean pharmacokinetic parameters of 7 analytes in rat plasma (n¼5).
Parametern Oroxylin
A-7-O-
glucuronide
Wogonoside Liquiritigenin 5-O-
Methylvisammiol
Cimifugin Glycyrrhizic
acid
Glycyrrhetinic
acid
AUC0t (min ng/mL) 12525 38749 112.9 1299 18342 298.6 7438
AUC0N (min ng/mL) 14829 44912 114.7 1299 18441 355.5 9415
MRT0t (h) 14.2 14.5 12.5 7.8 7.1 16.2 15.7
MRT0N (h) 18.4 18.5 12.8 7.9 7.1 18.4 24.4
T1/2 (h) 7.7 8.4 3.1 0.7 2.5 7.8 17.4
Tmax (h) 0.083 16 0.083 8 3 0.33 19
Vz/F (L/kg) 1499.6 542.2 77051 1549.4 392.1 63757 5322.1
CLz/F (L/H/kg) 134.9 44.53 17434 1539.1 108.5 5625.5 212.4
Cmax (mg/L) 1200 2362 20.3 338.0 2018 23.24 760.7
nAll pharmacokinetic parameters are calculated from plasma concentration–time proﬁles.
Yilin Wang et al.196glycyrrhizic acid and glycyrrhetinic acid in rat plasma were
similar and showed multiple-peak phenonmen; however, the
concentration of glycyrrhetinic acid in rat plasma was sig-
niﬁcantly higher than that of glycyrrhizic acid and Tmax of
glycyrrhetinic acid (19 h) was the extremely longest among the
7 constituents. Glycyrrhizic acid showed the lowest Cmax and
AUC among the 7 constituents. Takeda et al.18 reported that
glycyrrhetinic acid with higher concentration than glycyrrhizic
acid was detected in rat plasma after oral administration of
glycyrrhizic acid to rats, and glycyrrhizic acid was transformed
to glycyrrhetinic acid in rats. These two compounds have the
same parent nucleus, but two glucuronic acid groups con-
tained in glycyrrhizic acid structure rather than glycyrrhetinic
acid, so the metabolism easily happened between glycyrrhizic
acid and glycyrrhetinic acid. Due to easy absorption of
glycyrrhetinic acid in rat plasma and the each other’s bio-
transformation, the concentration of glycyrrhetinic acid in rat
plasm was enriched.
The concentrations of liquiritigenin, oroxylin A-7-O-glucur-
onide and cimifugin were at similar level about 1 mg/mL in
active fraction, but these three components showed very
different pharmacokinetic characterization. Oroxylin A-7-O-
glucuronide and cimifugin exhibited higher Cmax and AUC;
however, liquiritigenin showed the lowest Cmax and AUC.
Their concentration–time curves also exhibited the double-
peak phenomenon.4. Conclusions
In this study, determination of the 7 analytes by HPLC–MS
and HPLC–MS/MS methods in rat plasma have been estab-
lished and validated for the ﬁrst time. The established methods
are simple, rapid, sensitive and reliable, which have been
successfully applied to pharmacokinetic study after oral
administration of the active fraction of XXMD to rats. The
pharmacokinetic study of the 7 components after oral admin-
istration of the active fraction of XXMD to rats showed that
the pharmacokinetics of active components such as wogono-
side, glycyrrhizic acid and glycyrrhetinic acid kept similar
characterization of multiple-peak regardless of whether extract
of herbs or pure compound was administrated to rats. The
different components with similar concentration levels such as
liquiritigenin, oroxylin A-7-O-glucuronide and cimifugin incomplex prescription exhibited different exposure levels to
rats, and might be due to the effects of complex matrix on
absorption. This research could provide useful references for
the pharmacokinetic study of traditional Chinese medicine.Acknowledgment
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